To Be Discontinued Injection Endocrinology/Metabolism
Doxercalciferol Injection · 275 days since initial FDA posting
FDA lists Doxercalciferol Injection as To Be Discontinued (Sanofi-Aventis U.S. LLC).
No availability text on this FDA row.
Doxercalciferol Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Doxercalciferol Injection
- Manufacturer
- Sanofi-Aventis U.S. LLC
- Dosage Form
- Injection
- Presentation
- Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1)
- Package NDC
- 58468-0127-1
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Dec 10, 2025
- Last Updated
- Dec 10, 2025
- Therapeutic Category
- Endocrinology/Metabolism
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Doxercalciferol Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.